دورية أكاديمية
أعرض في EDS

Cutting edge of genetically modified pigs targeting complement activation for xenotransplantation.

التفاصيل البيبلوغرافية
العنوان: Cutting edge of genetically modified pigs targeting complement activation for xenotransplantation.
المؤلفون: Sun Q; Department of Endocrinology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China., Song SY; Department of Neuroscience, Baylor College of Medicine, Houston, TX, United States., Ma J; School of Pharmacy, Guangxi University of Chinese Medicine, Nanning, China., Li D; Department of Pharmacy, Longquanyi District of Chengdu Maternity & Child Health Care Hospital, Chengdu, China., Wang Y; Department of Critical Care Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China., Yang Z; School of Pharmacy, Guangxi University of Chinese Medicine, Nanning, China., Wang Y; Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Center of Organ Transplantation, Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.
المصدر: Frontiers in immunology [Front Immunol] 2024 Apr 04; Vol. 15, pp. 1383936. Date of Electronic Publication: 2024 Apr 04 (Print Publication: 2024).
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مواضيع طبية MeSH: Graft Rejection*/prevention & control , Complement Activation*, Animals ; Humans ; Swine ; Transplantation, Heterologous ; Animals, Genetically Modified ; Retrospective Studies ; Complement System Proteins
مستخلص: In the quest to address the critical shortage of donor organs for transplantation, xenotransplantation stands out as a promising solution, offering a more abundant supply of donor organs. Yet, its widespread clinical adoption remains hindered by significant challenges, chief among them being immunological rejection. Central to this issue is the role of the complement system, an essential component of innate immunity that frequently triggers acute and chronic rejection through hyperacute immune responses. Such responses can rapidly lead to transplant embolism, compromising the function of the transplanted organ and ultimately causing graft failure. This review delves into three key areas of xenotransplantation research. It begins by examining the mechanisms through which xenotransplantation activates both the classical and alternative complement pathways. It then assesses the current landscape of xenotransplantation from donor pigs, with a particular emphasis on the innovative strides made in genetically engineering pigs to evade complement system activation. These modifications are critical in mitigating the discordance between pig endogenous retroviruses and human immune molecules. Additionally, the review discusses pharmacological interventions designed to support transplantation. By exploring the intricate relationship between the complement system and xenotransplantation, this retrospective analysis not only underscores the scientific and clinical importance of this field but also sheds light on the potential pathways to overcoming one of the major barriers to the success of xenografts. As such, the insights offered here hold significant promise for advancing xenotransplantation from a research concept to a viable clinical reality.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 Sun, Song, Ma, Li, Wang, Yang and Wang.)
References: Xenotransplantation. 2006 Nov;13(6):488-99. (PMID: 17059572)
Immunobiology. 2010;215(1):1-11. (PMID: 19783065)
Trends Biotechnol. 2013 Jul;31(7):397-405. (PMID: 23664777)
N Engl J Med. 2022 May 19;386(20):1889-1898. (PMID: 35584156)
Protein Cell. 2010 Nov;1(11):1033-49. (PMID: 21153520)
Hepatobiliary Pancreat Dis Int. 2022 Dec;21(6):516-526. (PMID: 36376226)
Lancet. 1975 Aug 9;2(7928):248-50. (PMID: 49798)
Viruses. 2021 Oct 26;13(11):. (PMID: 34834962)
Front Immunol. 2015 Jan 22;6:1. (PMID: 25657648)
Int J Surg. 2015 Nov;23(Pt B):217-222. (PMID: 26231992)
J Surg Res. 2000 May 15;90(2):119-25. (PMID: 10792951)
Sci China C Life Sci. 2006 Apr;49(2):164-71. (PMID: 16704120)
Burns. 2018 Nov;44(7):1738-1749. (PMID: 29602717)
Mol Immunol. 2011 Aug;48(14):1631-42. (PMID: 21549429)
Adv Immunol. 1996;61:201-83. (PMID: 8834497)
Nat Biotechnol. 2007 Jul;25(7):778-85. (PMID: 17603475)
Curr Opin Organ Transplant. 2013 Aug;18(4):421-9. (PMID: 23838647)
Transpl Int. 1994 Aug;7(5):324-8. (PMID: 7993568)
Cell Mol Immunol. 2019 Apr;16(4):350-356. (PMID: 30804476)
Biol Reprod. 1997 Nov;57(5):1089-95. (PMID: 9369175)
J Immunol. 1974 Jul;113(1):348-58. (PMID: 4134064)
J Reprod Dev. 2021 Jun 21;67(3):177-187. (PMID: 33840678)
Nat Biotechnol. 2013 Jan;31(1):76-81. (PMID: 23242165)
Virology. 2001 Jul 5;285(2):177-80. (PMID: 11437652)
Am J Transplant. 2012 Mar;12(3):763-71. (PMID: 22070772)
Mol Immunol. 2007 Jan;44(1-3):73-81. (PMID: 16884774)
Proc (Bayl Univ Med Cent). 2012 Jan;25(1):49-57. (PMID: 22275786)
Am J Transplant. 2011 Dec;11(12):2593-602. (PMID: 21883917)
J Exp Med. 1985 Jul 1;162(1):75-92. (PMID: 2409211)
Transplantation. 1998 Mar 27;65(6):832-7. (PMID: 9539096)
Anticancer Drugs. 2019 Aug;30(7):e0770. (PMID: 30829654)
Nature. 2022 Jan;601(7893):305-306. (PMID: 35031782)
Nat Rev Drug Discov. 2015 Dec;14(12):857-77. (PMID: 26493766)
Am J Transplant. 2008 Dec;8(12):2516-26. (PMID: 19032222)
Transpl Immunol. 2002 May;9(2-4):257-70. (PMID: 12180840)
Mol Biotechnol. 2017 Oct;59(9-10):435-444. (PMID: 28698981)
Transplant Proc. 2005 Nov;37(9):4103-6. (PMID: 16386637)
Arch Virol. 2008;153(8):1421-6. (PMID: 18584115)
J Virol. 2001 Mar;75(6):2771-5. (PMID: 11222700)
Nat Biotechnol. 2007 Nov;25(11):1256-64. (PMID: 17989688)
Zygote. 2009 May;17(2):101-8. (PMID: 19063773)
J Exp Med. 1986 Jan 1;163(1):221-6. (PMID: 2416869)
Semin Immunol. 2016 Jun;28(3):223-40. (PMID: 27346521)
Adv Immunol. 1976;24:1-35. (PMID: 798473)
Transplant Proc. 1992 Apr;24(2):488-9. (PMID: 1566398)
Cell. 2014 Jun 5;157(6):1262-1278. (PMID: 24906146)
Mol Reprod Dev. 2010 Mar;77(3):209-21. (PMID: 19998476)
Mol Immunol. 2015 Oct;67(2 Pt A):117-30. (PMID: 25697848)
Biochem Biophys Res Commun. 2010 Oct 1;400(4):667-72. (PMID: 20816662)
Semin Immunol. 2016 Jun;28(3):208-22. (PMID: 27321574)
Rheum Dis Clin North Am. 2010 Feb;36(1):161-72, x. (PMID: 20202597)
Science. 2013 Feb 15;339(6121):823-6. (PMID: 23287722)
Am J Transplant. 2022 Apr;22(4):1037-1053. (PMID: 35049121)
Transplantation. 2003 Mar 15;75(5):697-702. (PMID: 12640312)
PLoS One. 2013 May 21;8(5):e63241. (PMID: 23704897)
Transplantation. 1995 Feb 15;59(3):410-6. (PMID: 7871572)
J Diabetes. 2016 Jul;8(4):483-93. (PMID: 26987992)
Transplant Proc. 2006 Jun;38(5):1618-21. (PMID: 16797369)
فهرسة مساهمة: Keywords: C3a; C3b; complement systems; genetically modified pigs; xenotransplantation
المشرفين على المادة: 9007-36-7 (Complement System Proteins)
تواريخ الأحداث: Date Created: 20240419 Date Completed: 20240422 Latest Revision: 20240425
رمز التحديث: 20240425
مُعرف محوري في PubMed: PMC11024274
DOI: 10.3389/fimmu.2024.1383936
PMID: 38638432
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-3224
DOI:10.3389/fimmu.2024.1383936